OPCH Stock Forecast & Price Target

Option Care Health is expected to experience a negative share reaction due to a higher expected CID H/W and a steeply implied ramp in 2H adj. EBITDA. However, the company has identified various levers to drive growth in 2H, and with 185 locations across 43 states and a strong portfolio split between Acute and Chronic therapies, Option Care has the potential to deliver consistent beats and raises while the Advanced Practitioner model could lead to substantial market penetration. Ultimately, a number of company-specific risks could impact the stock in both directions, but the positive outlook is supported by these factors.

Option Care Health is facing a mixed-bag first quarter, with a significant shortfall in revenue and lowered financial guidance for 2026. With a steep ramp in adjusted EBITDA needed to achieve the bottom of the guidance and concerns over the company's ability to deliver, there is a negative outlook on the stock. Cash generation and gross margin are also potential concerns that investors should closely monitor. Despite this, Option Care remains well-positioned to compete in the home/alternate site infusion space and could see improved top-line growth and profitability in the future. However, there is still some risk of further downside, and the current price weakness may present a buying opportunity for long-term investors.